Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel
Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma.
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma. 
